首页> 外文OA文献 >Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial
【2h】

Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial

机译:关节腔内皮质类固醇与关节内类固醇与氨甲蝶呤治疗少关节型青少年特发性关节炎:一项多中心,前瞻性,随机,开放标签试验

摘要

Background Little evidence-based information is available to guide the treatment of oligoarticular juvenile idiopathic arthritis. We aimed to investigate whether oral methotrexate increases the efficacy of intra-articular corticosteroid therapy. Methods We did this prospective, open-label, randomised trial at ten hospitals in Italy. Using a concealed computer-generated list, children younger than 18 years with oligoarticular-onset disease were randomly assigned (1:1) to intra-articular corticosteroids alone or in combination with oral methotrexate (15 mg/m2; maximum 20 mg). Corticosteroids used were triamcinolone hexacetonide (shoulder, elbow, wrist, knee, and tibiotalar joints) or methylprednisolone acetate (ie, subtalar and tarsal joints). We did not mask patients or investigators to treatment assignments. Our primary outcome was the proportion of patients in the intention-to-treat population who had remission of arthritis in all injected joints at 12 months. This trial is registered with European Union Clinical Trials Register, EudraCT number 2008-006741-70. Findings Between July 7, 2009, and March 31, 2013, we screened 226 participants and randomly assigned 102 to intra-articular corticosteroids alone and 105 to intra-articular corticosteroids plus methotrexate. 33 (32%) patients assigned to intra-articular corticosteroids alone and 39 (37%) assigned to intra-articular corticosteroids and methotrexate therapy had remission of arthritis in all injected joints (p=0·48). Adverse events were recorded for 20 (17%) patients who received methotrexate, which led to permanent treatment discontinuation in two patients (one due to increased liver transaminases and one due to gastrointestinal discomfort). No patient had a serious adverse event. Interpretation Concomitant administration of methotrexate did not augment the effectiveness of intra-articular corticosteroid therapy. Future studies are needed to define the optimal therapeutic strategies for oligoarticular juvenile idiopathic arthritis. Funding Italian Agency of Drug Evaluation.
机译:背景技术很少有循证信息可用于指导少关节型青少年特发性关节炎的治疗。我们旨在研究口服甲氨蝶呤是否会增加关节内糖皮质激素治疗的疗效。方法我们在意大利的十家医院进行了这项前瞻性,开放标签,随机试验。使用隐藏的计算机生成的清单,将18岁以下患有少关节疾病的儿童随机分配(1:1)单独或联合口服甲氨蝶呤(15 mg / m2;最大20 mg)进行关节内激素治疗。所使用的皮质类固醇为曲安西龙己烯酮(肩,肘,腕,膝和胫距关节)或醋酸甲泼尼龙(即距下和关节)。我们没有掩盖患者或研究者的治疗任务。我们的主要结局是在意向治疗人群中,在12个月内所有注射关节中关节炎缓解的患者比例。该试验已在欧盟临床试验注册中心注册,EudraCT编号为2008-006741-70。研究结果在2009年7月7日至2013年3月31日之间,我们筛选了226名参与者,并随机分配了102名单独使用关节内皮质类固醇和105名使用关节内皮质类固醇加甲氨蝶呤。仅33例(32%)被分配为关节内激素治疗的患者和39名(37%)被分配为关节内激素治疗和甲氨蝶呤治疗的患者在所有注射的关节中均缓解了关节炎(p = 0·48)。记录了接受甲氨蝶呤的20名患者(17%)的不良事件,导致两名患者永久停药(一名是由于肝转氨酶升高,另一名是由于胃肠道不适)。没有患者发生严重不良事件。解释甲氨蝶呤的同时使用并未增加关节内糖皮质激素治疗的有效性。需要进一步的研究来确定少关节型青少年特发性关节炎的最佳治疗策略。资助意大利药品评估局。

相似文献

  • 外文文献
  • 中文文献

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号